theragenomik: biomarker
thasso hat für Sie die Übersichtstabelle „theragenomische Biomarker“ im Zusammenhang mit ihren Arzneimitteln, Indikationen und den zugehörigen FDA-Arzneimittelinformationen ((Labels), welche auf die betroffenen Patientengruppen verweisen können) erstellt. Grundlage für dieses Produkt ist die von der FDA veröffentlichte Liste der akzeptierten Biomarker. Arzneimittel sind mit den entsprechenden Arzneimittelinformationen verknüpft, auf welche unter Drugs@FDA zugegriffen werden kann.
- Bitte beachten Sie, dass in dieser Tabelle der pharmakologische Wirkstoff (API) aufgeführt ist, im Gegensatz zu den Markennamen. Markennamen können erheblich variieren, d. h. Handelsnamen für außerhalb der USA zugelassene Arzneimittel können sich von denen in den USA unterscheiden, ebenso wie die Namen von Generika sowohl innerhalb als auch außerhalb der USA. Im Zweifelsfall wäre die Suche nach der API an erster Stelle eine gute Idee.
- Bitte beachten Sie auch, dass Sie eine ausführliche Version der “Table of Pharmacogenomic Biomarkers in Drug Labeling” herunterladen können, einschließlich vollständiger pharmakogenetischer (PGX)-bezogener Kennzeichnungstexte welche aus den vollständigen jeweiligen Arzneimittelinformationen entnommen sind.
Leider ist diese integrierte theragenomische Informations-Tabelle vorläufig nur in Englisch (auf den USA und damit der FDA basierend) verfügbar. Eine entsprechende Version mit deutschen (BfArM), österreichischen (ARGES), oder schweizerischen (Swissmedic) Inhalten ist geplant.
Letzte Aktualisierung: 15. März 2019
| Drug | Therapeutic Area* | Biomarker† | Labeling Sections |
|---|---|---|---|
| Abacavir | Infectious Diseases | HLA-B | Boxed Warning, Dosage and Administration, Contraindications, Warnings and Precautions |
| Abemaciclib (1) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Abemaciclib (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Ado-Trastuzumab Emtansine | Oncology | ERBB2 (HER2) | Indications and Usage, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Afatinib | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Alectinib | Oncology | ALK | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Amifampridine | Neurology | NAT2 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Amitriptyline | Psychiatry | CYP2D6 | Precautions |
| Amoxapine | Psychiatry | CYP2D6 | Precautions |
| Amphetamine | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Anastrozole | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Drug Interactions, Clinical Studies |
| Arformoterol (1) | Pulmonary | UGT1A1 | Clinical Pharmacology |
| Arformoterol (2) | Pulmonary | CYP2D6 | Clinical Pharmacology |
| Aripiprazole | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Aripiprazole Lauroxil | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Arsenic Trioxide | Oncology | PML-RARA | Indications and Usage |
| Articaine and Epinephrine (1) | Anesthesiology | G6PD | Warnings and Precautions |
| Articaine and Epinephrine (2) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions |
| Ascorbic Acid, PEG-3350, Potassium Chloride, Sodium Ascorbate, Sodium Chloride, and Sodium Sulfate | Gastroenterology | G6PD | Warnings and Precautions |
| Atezolizumab (1) | Oncology | CD274 (PD-L1) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Atezolizumab (2) | Oncology | Gene Signature (T-effector) | Clinical Studies |
| Atomoxetine | Psychiatry | CYP2D6 | Dosage and Administration, Warnings and Precautions, Adverse Reactions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| Avatrombopag (1) | Hematology | F2 (Prothrombin) | Warnings and Precautions |
| Avatrombopag (2) | Hematology | F5 (Factor V Leiden) | Warnings and Precautions |
| Avatrombopag (3) | Hematology | PROC | Warnings and Precautions |
| Avatrombopag (4) | Hematology | PROS1 | Warnings and Precautions |
| Avatrombopag (5) | Hematology | SERPINC1 (Antithrombin III) | Warnings and Precautions |
| Avelumab | Oncology | CD274 (PD-L1) | Clinical Studies |
| Azathioprine (1) | Rheumatology | TPMT | Dosage and Administration, Warnings, Precautions, Drug Interactions, Adverse Reactions, Clinical Pharmacology |
| Azathioprine (2) | Rheumatology | NUDT15 | Dosage and Administration, Warnings, Precautions, Adverse Reactions, Clinical Pharmacology |
| Belinostat | Oncology | UGT1A1 | Dosage and Administration, Clinical Pharmacology |
| Binimetinib (1) | Oncology | BRAF | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Binimetinib (2) | Oncology | UGT1A1 | Clinical Pharmacology |
| Blinatumomab | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Clinical Studies |
| Boceprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical Pharmacology |
| Bosutinib | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Brentuximab Vedotin (1) | Oncology | ALK | Clinical Studies |
| Brentuximab Vedotin (2) | Oncology | TNFRSF8 (CD30) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Brexpiprazole | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Brigatinib | Oncology | ALK | Indications and Usage, Adverse Reactions, Clinical Studies |
| Brivaracetam | Neurology | CYP2C19 | Clinical Pharmacology |
| Busulfan | Oncology | BCR-ABL1 (Philadelphia chromosome) | Clinical Studies |
| Cabozantinib | Oncology | RET | Clinical Studies |
| Capecitabine | Oncology | DPYD | Warnings and Precautions, Patient Counseling Information |
| Carbamazepine (1) | Neurology | HLA-B | Boxed Warning, Warnings, Precautions |
| Carbamazepine (2) | Neurology | HLA-A | Warnings |
| Carglumic Acid | Inborn Errors of Metabolism | NAGS | Indications and Usage, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Cariprazine | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Carisoprodol | Rheumatology | CYP2C19 | Use in Specific Populations, Clinical Pharmacology |
| Carvedilol | Cardiology | CYP2D6 | Drug Interactions, Clinical Pharmacology |
| Ceftriaxone (1) | Infectious Diseases | G6PD | Warnings |
| Ceftriaxone (2) | Infectious Diseases | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| Celecoxib | Rheumatology | CYP2C9 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Ceritinib | Oncology | ALK | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Cerliponase Alfa | Inborn Errors of Metabolism | TPP1 | Indications and Usage, Use in Specific Populations, Clinical Studies |
| Cetuximab (1) | Oncology | EGFR | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| Cetuximab (2) | Oncology | RAS | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| Cevimeline | Dental | CYP2D6 | Precautions |
| Chloroprocaine (1) | Anesthesiology | G6PD | Warnings |
| Chloroprocaine (2) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| Chloroquine | Infectious Diseases | G6PD | Precautions |
| Chlorpropamide | Endocrinology | G6PD | Precautions |
| Cisplatin | Oncology | TPMT | Adverse Reactions |
| Citalopram (1) | Psychiatry | CYP2C19 | Dosage and Administration, Warnings, Clinical Pharmacology |
| Citalopram (2) | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Clobazam | Neurology | CYP2C19 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Clomipramine | Psychiatry | CYP2D6 | Precautions |
| Clopidogrel | Cardiology | CYP2C19 | Boxed Warning, Warnings and Precautions, Clinical Pharmacology |
| Clozapine | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Cobimetinib | Oncology | BRAF | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Codeine | Anesthesiology | CYP2D6 | Boxed Warning, Warnings and Precautions, Use in Specific Populations, Patient Counseling Information |
| Crizotinib (1) | Oncology | ALK | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Crizotinib (2) | Oncology | ROS1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Dabrafenib (1) | Oncology | BRAF | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies, Patient Counseling Information |
| Dabrafenib (2) | Oncology | G6PD | Warnings and Precautions, Adverse Reactions, Patient Counseling Information |
| Dabrafenib (3) | Oncology | RAS | Dosage and Administration, Warnings and Precautions |
| Daclatasvir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Dacomitinib | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Dapsone (1) | Dermatology | G6PD | Warnings and Precautions, Use in Specific Populations |
| Dapsone (2) | Dermatology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions |
| Dapsone (3) | Infectious Diseases | G6PD | Precautions, Adverse Reactions, Overdosage |
| Darifenacin | Urology | CYP2D6 | Clinical Pharmacology |
| Dasabuvir, Ombitasvir, Paritaprevir, and Ritonavir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Dasatinib | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| Denileukin Diftitox | Oncology | IL2RA (CD25 antigen) | Indications and Usage, Warnings and Precautions, Clinical Studies |
| Desflurane | Anesthesiology | Nonspecific (Genetic Susceptibility to Malignant Hyperthermia) | Contraindications |
| Desipramine | Psychiatry | CYP2D6 | Precautions |
| Desvenlafaxine | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Deutetrabenazine | Neurology | CYP2D6 | Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology |
| Dexlansoprazole | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| Dextromethorphan and Quinidine | Neurology | CYP2D6 | Warnings and Precautions, Clinical Pharmacology |
| Diazepam | Neurology | CYP2C19 | Clinical Pharmacology |
| Dinutuximab | Oncology | MYCN | Clinical Studies |
| Docetaxel | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| Dolutegravir | Infectious Diseases | UGT1A1 | Clinical Pharmacology |
| Donepezil | Neurology | CYP2D6 | Clinical Pharmacology |
| Doxepin (1) | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Doxepin (2) | Psychiatry | CYP2C19 | Clinical Pharmacology |
| Dronabinol | Gastroenterology | CYP2C9 | Use in Specific Populations, Clinical Pharmacology |
| Drospirenone and Ethinyl Estradiol | Gynecology | CYP2C19 | Clinical Pharmacology |
| Duloxetine | Psychiatry | CYP2D6 | Drug Interactions |
| Durvalumab | Oncology | CD274 (PD-L1) | Clinical Pharmacology, Clinical Studies |
| Duvelisib | Oncology | Chromosome 17p | Clinical Studies |
| Efavirenz | Infectious Diseases | CYP2B6 | Clinical Pharmacology |
| Elagolix | Gynecology | SLCO1B1 | Clinical Pharmacology |
| Elbasvir and Grazoprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Eliglustat | Inborn Errors of Metabolism | CYP2D6 | Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Elosulfase | Inborn Errors of Metabolism | GALNS | Indications and Usage, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Eltrombopag (1) | Hematology | F5 (Factor V Leiden) | Warnings and Precautions |
| Eltrombopag (2) | Hematology | SERPINC1 (Antithrombin III) | Warnings and Precautions |
| Emapalumab-lzsg | Hematology | PRF1, RAB27A, SH2D1A, STXBP2, STX11, UNC13D, XIAP (Hemophagocytic Lymphohistiocytosis) | Clinical Studies |
| Enasidenib | Oncology | IDH2 | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| Encorafenib | Oncology | BRAF | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Enflurane | Anesthesiology | Nonspecific (Genetic Susceptibility to Malignant Hyperthermia) | Contraindications |
| Eribulin (1) | Oncology | ERBB2 (HER2) | Clinical Studies |
| Eribulin (2) | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| Erlotinib | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Erythromycin and Sulfisoxazole | Infectious Diseases | G6PD | Precautions |
| Escitalopram (1) | Psychiatry | CYP2D6 | Drug Interactions |
| Escitalopram (2) | Psychiatry | CYP2C19 | Adverse Reactions |
| Esomeprazole | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| Eteplirsen | Neurology | DMD | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Everolimus (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Drug Interactions, Use in Specific Populations, Clinical Studies |
| Everolimus (2) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Drug Interactions, Use in Specific Populations, Clinical Studies |
| Exemestane | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Clinical Studies |
| Fesoterodine | Urology | CYP2D6 | Drug Interactions, Clinical Pharmacology |
| Flibanserin (1) | Gynecology | CYP2C9 | Clinical Pharmacology |
| Flibanserin (2) | Gynecology | CYP2C19 | Adverse Reactions, Use in Specific Populations, Clinical Pharmacology |
| Flibanserin (3) | Gynecology | CYP2D6 | Clinical Pharmacology |
| Fluorouracil (1) | Dermatology | DPYD | Contraindications, Warnings |
| Fluorouracil (2) | Oncology | DPYD | Warnings and Precautions, Patient Counseling Information |
| Fluoxetine | Psychiatry | CYP2D6 | Precautions, Clinical Pharmacology |
| Flurbiprofen | Rheumatology | CYP2C9 | Clinical Pharmacology |
| Flutamide | Oncology | G6PD | Warnings |
| Fluvoxamine | Psychiatry | CYP2D6 | Drug Interactions |
| Formoterol (1) | Pulmonary | CYP2D6 | Clinical Pharmacology |
| Formoterol (2) | Pulmonary | CYP2C19 | Clinical Pharmacology |
| Fosphenytoin | Neurology | HLA-B | Warnings and Precautions |
| Fulvestrant (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Fulvestrant (2) | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Galantamine | Neurology | CYP2D6 | Clinical Pharmacology |
| Gefitinib (1) | Oncology | EGFR | Indications and Usage, Dosage and Administration, Clinical Studies |
| Gefitinib (2) | Oncology | CYP2D6 | Clinical Pharmacology |
| Gilteritinib | Oncology | FLT3 | Indications and Usage, Dosage and Administration, Clinical Studies |
| Glimepiride | Endocrinology | G6PD | Warnings and Precautions, Adverse Reactions |
| Glipizide | Endocrinology | G6PD | Precautions |
| Glyburide | Endocrinology | G6PD | Precautions |
| Goserelin | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Clinical Studies |
| Hydralazine | Cardiology | Nonspecific (NAT) | Clinical Pharmacology |
| Hydroxychloroquine | Infectious Diseases | G6PD | Precautions, Adverse Reactions |
| Ibrutinib (1) | Oncology | Chromosome 17p | Indications and Usage, Clinical Studies |
| Ibrutinib (2) | Oncology | Chromosome 11q | Clinical Studies |
| Iloperidone | Psychiatry | CYP2D6 | Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology |
| Imatinib (1) | Oncology | KIT | Indications and Usage, Dosage and Administration, Clinical Studies |
| Imatinib (2) | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Imatinib (3) | Oncology | PDGFRB | Indications and Usage, Dosage and Administration, Clinical Studies |
| Imatinib (4) | Oncology | FIP1L1-PDGFRA | Indications and Usage, Dosage and Administration, Clinical Studies |
| Imipramine | Psychiatry | CYP2D6 | Precautions |
| Indacaterol | Pulmonary | UGT1A1 | Clinical Pharmacology |
| Inotersen | Neurology | TTR | Adverse Reactions, Clinical Pharmacology |
| Inotuzumab Ozogamicin | Oncology | BCR-ABL1 (Philadelphia chromosome) | Clinical Studies |
| Ipilimumab (1) | Oncology | HLA-A | Clinical Studies |
| Ipilimumab (2) | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Irinotecan | Oncology | UGT1A1 | Dosage and Administration, Warnings and Precautions, Clinical Pharmacology |
| Isoflurane | Anesthesiology | Nonspecific (Genetic Susceptibility to Malignant Hyperthermia) | Contraindications |
| Isoniazid, Pyrazinamide, and Rifampin | Infectious Diseases | Nonspecific (NAT) | Clinical Pharmacology |
| Isosorbide Dinitrate | Cardiology | CYB5R | Overdosage |
| Isosorbide Mononitrate | Cardiology | CYB5R | Overdosage |
| Ivacaftor | Pulmonary | CFTR | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Ivacaftor and Lumacaftor | Pulmonary | CFTR | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Ivacaftor and Tezacaftor | Pulmonary | CFTR | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Ivosidenib | Oncology | IDH1 | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| Ixabepilone (1) | Oncology | ERBB2 (HER2) | Clinical Studies |
| Ixabepilone (2) | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| Lacosamide | Neurology | CYP2C19 | Clinical Pharmacology |
| Lansoprazole | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| Lapatinib (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Lapatinib (2) | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Lapatinib (3) | Oncology | HLA-DQA1, HLA-DRB1 | Clinical Pharmacology |
| Larotrectinib | Oncology | NTRK | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Ledipasvir and Sofosbuvir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Lenalidomide | Hematology | Chromosome 5q | Boxed Warning, Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Lesinurad | Rheumatology | CYP2C9 | Drug Interactions, Clinical Pharmacology |
| Letrozole | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Lidocaine and Prilocaine (1) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions |
| Lidocaine and Prilocaine (2) | Anesthesiology | G6PD | Warnings and Precautions, Clinical Pharmacology |
| Lidocaine and Tetracaine (1) | Anesthesiology | G6PD | Warnings and Precautions |
| Lidocaine and Tetracaine (2) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions |
| Lofexidine | Anesthesiology | CYP2D6 | Use in Specific Populations |
| Lorlatinib (1) | Oncology | ALK | Indications and Usage, Adverse Reactions, Clinical Studies |
| Lorlatinib (2) | Oncology | ROS1 | Adverse Reactions |
| Lusutrombopag (1) | Hematology | F2 (Prothrombin) | Warnings and Precautions |
| Lusutrombopag (2) | Hematology | F5 (Factor V Leiden) | Warnings and Precautions |
| Lusutrombopag (3) | Hematology | PROC | Warnings and Precautions |
| Lusutrombopag (4) | Hematology | PROS1 | Warnings and Precautions |
| Lusutrombopag (5) | Hematology | SERPINC1 (Antithrombin III) | Warnings and Precautions |
| Mafenide | Infectious Diseases | G6PD | Warnings, Adverse Reactions |
| Meclizine | Neurology | CYP2D6 | Clinical Pharmacology |
| Mepivacaine (1) | Anesthesiology | G6PD | Warnings |
| Mepivacaine (2) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| Mercaptopurine (1) | Oncology | TPMT | Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology |
| Mercaptopurine (2) | Oncology | NUDT15 | Dosage and Administration, Warnings and Precautions, Clinical Pharmacology |
| Methylene Blue | Hematology | G6PD | Contraindications, Warnings and Precautions |
| Metoclopramide (1) | Gastroenterology | CYB5R | Use in Specific Populations, Overdosage |
| Metoclopramide (2) | Gastroenterology | G6PD | Use in Specific Populations, Overdosage |
| Metoclopramide (3) | Gastroenterology | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| Metoprolol | Cardiology | CYP2D6 | Drug Interactions, Clinical Pharmacology |
| Midostaurin (1) | Oncology | FLT3 | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Midostaurin (2) | Oncology | NPM1 | Clinical Studies |
| Midostaurin (3) | Oncology | KIT | Clinical Studies |
| Migalastat | Inborn Errors of Metabolism | GLA | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| Mirabegron | Urology | CYP2D6 | Clinical Pharmacology |
| Mivacurium | Anesthesiology | BCHE | Warnings, Precautions, Clinical Pharmacology |
| Modafinil | Psychiatry | CYP2D6 | Clinical Pharmacology |
| Mycophenolic Acid | Transplantation | HPRT1 | Warnings and Precautions |
| Nalidixic Acid | Infectious Diseases | G6PD | Precautions, Adverse Reactions |
| Nebivolol | Cardiology | CYP2D6 | Dosage and Administration, Clinical Pharmacology |
| Nefazodone | Psychiatry | CYP2D6 | Precautions |
| Neratinib (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Neratinib (2) | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| Nilotinib (1) | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Nilotinib (2) | Oncology | UGT1A1 | Clinical Pharmacology |
| Niraparib | Oncology | BRCA | Clinical Studies |
| Nitrofurantoin | Infectious Diseases | G6PD | Warnings, Adverse Reactions |
| Nivolumab (1) | Oncology | BRAF | Indications and Usage, Adverse Reactions, Clinical Studies |
| Nivolumab (2) | Oncology | CD274 (PD-L1) | Clinical Pharmacology, Clinical Studies |
| Nivolumab (3) | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Clinical Studies |
| Nortriptyline | Psychiatry | CYP2D6 | Precautions |
| Nusinersen | Neurology | SMN2 | Clinical Pharmacology, Clinical Studies |
| Obinutuzumab | Oncology | MS4A1 (CD20 antigen) | Clinical Studies |
| Olaparib (1) | Oncology | BRCA | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| Olaparib (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Olaparib (3) | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Clinical Studies |
| Olaratumab | Oncology | PDGFRA | Clinical Studies |
| Omacetaxine | Oncology | BCR-ABL1 (Philadelphia chromosome) | Clinical Studies |
| Ombitasvir, Paritaprevir, and Ritonavir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Omeprazole | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| Ondansetron | Gastroenterology | CYP2D6 | Clinical Pharmacology |
| Osimertinib | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Ospemifene (1) | Gynecology | CYP2C9 | Clinical Pharmacology |
| Ospemifene (2) | Gynecology | CYP2B6 | Clinical Pharmacology |
| Oxcarbazepine | Neurology | HLA-B | Warnings and Precautions |
| Oxymetazoline and Tetracaine (1) | Anesthesiology | G6PD | Warnings and Precautions |
| Oxymetazoline and Tetracaine (2) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions |
| Palbociclib (1) | Oncology | ESR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Palbociclib (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Palonosetron | Gastroenterology | CYP2D6 | Clinical Pharmacology |
| Panitumumab (1) | Oncology | EGFR | Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Panitumumab (2) | Oncology | RAS | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| Pantoprazole | Gastroenterology | CYP2C19 | Clinical Pharmacology |
| Parathyroid Hormone | Inborn Errors of Metabolism | CASR | Indications and Usage, Clinical Studies |
| Paroxetine | Psychiatry | CYP2D6 | Drug Interactions |
| Patisiran | Neurology | TTR | Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Pazopanib (1) | Oncology | UGT1A1 | Clinical Pharmacology |
| Pazopanib (2) | Oncology | HLA-B | Clinical Pharmacology |
| Peginterferon Alfa-2b | Infectious Diseases | IFNL3 (IL28B) | Clinical Pharmacology |
| Pegloticase | Rheumatology | G6PD | Boxed Warning, Contraindications, Warnings and Precautions, Patient Counseling Information |
| Pembrolizumab (1) | Oncology | BRAF | Adverse Reactions, Clinical Studies |
| Pembrolizumab (2) | Oncology | CD274 (PD-L1) | Indications and Usage, Dosage and Administration, Clinical Studies |
| Pembrolizumab (3) | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Dosage and Administration, Use in Specific Populations, Clinical Studies |
| Perphenazine | Psychiatry | CYP2D6 | Precautions, Clinical Pharmacology |
| Pertuzumab (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Pertuzumab (2) | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| Phenytoin (1) | Neurology | CYP2C9 | Clinical Pharmacology |
| Phenytoin (2) | Neurology | CYP2C19 | Clinical Pharmacology |
| Phenytoin (3) | Neurology | HLA-B | Warnings |
| Pimozide | Psychiatry | CYP2D6 | Dosage and Administration, Precautions |
| Piroxicam | Rheumatology | CYP2C9 | Clinical Pharmacology |
| Ponatinib | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Prasugrel (1) | Cardiology | CYP2C19 | Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Prasugrel (2) | Cardiology | CYP2C9 | Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Prasugrel (3) | Cardiology | CYP3A5 | Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Prasugrel (4) | Cardiology | CYP2B6 | Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| Primaquine (1) | Infectious Diseases | G6PD | Contraindications, Warnings, Precautions, Adverse Reactions, Overdosage |
| Primaquine (2) | Infectious Diseases | CYB5R | Precautions, Adverse Reactions |
| Probenecid | Rheumatology | G6PD | Adverse Reactions |
| Procainamide | Cardiology | Nonspecific (NAT) | Adverse Reactions, Clinical Pharmacology |
| Propafenone | Cardiology | CYP2D6 | Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology |
| Propranolol | Cardiology | CYP2D6 | Clinical Pharmacology |
| Protriptyline | Psychiatry | CYP2D6 | Precautions |
| Quinidine | Cardiology | CYP2D6 | Precautions |
| Quinine Sulfate (1) | Infectious Diseases | G6PD | Contraindications |
| Quinine Sulfate (2) | Infectious Diseases | CYP2D6 | Drug Interactions |
| Rabeprazole | Gastroenterology | CYP2C19 | Clinical Pharmacology |
| Raloxifene | Oncology | ESR (Hormone Receptor) | Clinical Studies |
| Raltegravir | Infectious Diseases | UGT1A1 | Clinical Pharmacology |
| Rasburicase (1) | Oncology | G6PD | Boxed Warning, Contraindications, Warnings and Precautions |
| Rasburicase (2) | Oncology | CYB5R | Boxed Warning, Contraindications, Warnings and Precautions |
| Ribociclib (1) | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Ribociclib (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Risperidone | Psychiatry | CYP2D6 | Drug Interactions, Clinical Pharmacology |
| Rituximab | Oncology | MS4A1 (CD20 antigen) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Rivaroxaban | Cardiology | F5 (Factor V Leiden) | Clinical Studies |
| Ropivacaine (1) | Anesthesiology | G6PD | Warnings |
| Ropivacaine (2) | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| Rosuvastatin | Endocrinology | SLCO1B1 | Clinical Pharmacology |
| Rucaparib (1) | Oncology | BRCA | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| Rucaparib (2) | Oncology | CYP2D6 | Clinical Pharmacology |
| Rucaparib (3) | Oncology | CYP1A2 | Clinical Pharmacology |
| Sevoflurane | Anesthesiology | RYR1 | Warnings |
| Simeprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical Pharmacology, Clinical Studies |
| Sodium Nitrite (1) | Toxicology | G6PD | Warnings and Precautions |
| Sodium Nitrite (2) | Toxicology | Nonspecific (Congenital Methemoglobinemia) | Boxed Warning, Warnings and Precautions |
| Sodium Phenylbutyrate | Inborn Errors of Metabolism | ASS1, CPS1, OTC (Urea Cycle Disorders) | Indications and Usage, Dosage and Administration |
| Sofosbuvir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Sofosbuvir and Velpatasvir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Sofosbuvir, Velpatasvir, and Voxilaprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| Succimer | Hematology | G6PD | Clinical Pharmacology |
| Succinylcholine | Anesthesiology | BCHE | Warnings, Precautions |
| Sulfadiazine | Infectious Diseases | G6PD | Warnings |
| Sulfamethoxazole and Trimethoprim (1) | Infectious Diseases | G6PD | Precautions |
| Sulfamethoxazole and Trimethoprim (2) | Infectious Diseases | Nonspecific (NAT) | Precautions |
| Sulfasalazine (1) | Gastroenterology | G6PD | Precautions |
| Sulfasalazine (2) | Gastroenterology | Nonspecific (NAT) | Clinical Pharmacology |
| Tafenoquine | Infectious Diseases | G6PD | Dosage and Administration, Contraindications, Warnings and Precautions, Use in Specific Populations, Patient Counseling Information |
| Talazoparib (1) | Oncology | BRCA | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| Talazoparib (2) | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Tamoxifen (1) | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| Tamoxifen (2) | Oncology | F5 (Factor V Leiden) | Warnings and Precautions |
| Tamoxifen (3) | Oncology | F2 (Prothrombin) | Warnings and Precautions |
| Tamoxifen (4) | Oncology | CYP2D6 | Clinical Pharmacology |
| Tamsulosin | Urology | CYP2D6 | Warnings and Precautions, Adverse Interactions, Clinical Pharmacology |
| Telaprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical Pharmacology, Clinical Studies |
| Tetrabenazine | Neurology | CYP2D6 | Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology |
| Thioguanine (1) | Oncology | TPMT | Dosage and Administration, Warnings, Precautions, Clinical Pharmacology |
| Thioguanine (2) | Oncology | NUDT15 | Dosage and Administration, Warnings, Precautions, Clinical Pharmacology |
| Thioridazine | Psychiatry | CYP2D6 | Contraindications, Warnings, Precautions |
| Ticagrelor | Cardiology | CYP2C19 | Clinical Pharmacology |
| Tolazamide | Endocrinology | G6PD | Precautions |
| Tolbutamide | Endocrinology | G6PD | Precautions |
| Tolterodine | Urology | CYP2D6 | Warnings and Precautions, Drug Interactions, Clinical Pharmacology |
| Toremifene | Oncology | ESR (Hormone Receptor) | Indications and Usage, Clinical Studies |
| Tramadol | Anesthesiology | CYP2D6 | Boxed Warning, Warnings, Precautions, Use in Specific Populations, Clinical Pharmacology |
| Trametinib (1) | Oncology | BRAF | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies, Patient Counseling Information |
| Trametinib (2) | Oncology | G6PD | Adverse Reactions |
| Trametinib (3) | Oncology | RAS | Warnings and Precautions |
| Trastuzumab (1) | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| Trastuzumab (2) | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| Tretinoin | Oncology | PML-RARA | Indications and Usage, Warnings, Clinical Pharmacology |
| Trimipramine | Psychiatry | CYP2D6 | Precautions |
| Umeclidinium | Pulmonary | CYP2D6 | Clinical Pharmacology |
| Ustekinumab | Dermatology and Gastroenterology | IL12A, IL12B, IL23A | Warnings and Precautions |
| Valbenazine | Neurology | CYP2D6 | Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology |
| Valproic Acid (1) | Neurology | POLG | Boxed Warning, Contraindications, Warnings and Precautions |
| Valproic Acid (2) | Neurology | Nonspecific (Urea Cycle Disorders) | Contraindications, Warnings and Precautions |
| Vemurafenib (1) | Oncology | BRAF | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies, Patient Counseling Information |
| Vemurafenib (2) | Oncology | RAS | Warnings and Precautions, Adverse Reactions |
| Venetoclax (1) | Oncology | Chromosome 17p | Indications and Usage, Clinical Studies |
| Venetoclax (2) | Oncology | Chromosome 11q | Clinical Studies |
| Venetoclax (3) | Oncology | TP53 | Clinical Studies |
| Venetoclax (4) | Oncology | IDH1 | Clinical Studies |
| Venetoclax (5) | Oncology | IDH2 | Clinical Studies |
| Venetoclax (6) | Oncology | IGH | Clinical Studies |
| Venetoclax (7) | Oncology | NPM1 | Clinical Studies |
| Venlafaxine | Psychiatry | CYP2D6 | Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| Vincristine | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Adverse Reactions, Clinical Studies |
| Voriconazole | Infectious Diseases | CYP2C19 | Clinical Pharmacology |
| Vortioxetine | Psychiatry | CYP2D6 | Dosage and Administration, Clinical Pharmacology |
| Warfarin (1) | Hematology | CYP2C9 | Dosage and Administration, Drug Interactions, Clinical Pharmacology |
| Warfarin (2) | Hematology | VKORC1 | Dosage and Administration, Clinical Pharmacology |
| Warfarin (3) | Hematology | PROS1 | Warnings and Precautions |
| Warfarin (4) | Hematology | PROC | Warnings and Precautions |